Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.

@article{Denisuik2013MolecularEO,
  title={Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.},
  author={Andrew J Denisuik and Philippe R. S. Lagac{\'e}-Wiens and Johann D. D. Pitout and Michael R. Mulvey and Patricia J Simner and Franil Tailor and James A Karlowsky and Daryl J. Hoban and Heather J. Adam and George G Zhanel},
  journal={The Journal of antimicrobial chemotherapy},
  year={2013},
  volume={68 Suppl 1},
  pages={i57-65}
}
OBJECTIVES To assess the proportion of Escherichia coli and Klebsiella pneumoniae from Canadian hospitals that produce extended-spectrum β-lactamases (ESBLs), AmpC β-lactamases and carbapenemases, as well as to describe the patterns of antibiotic resistance and molecular characteristics of these organisms. METHODS Some 5451 E. coli and 1659 K. pneumoniae were collected from 2007 to 2011 inclusive as part of the ongoing CANWARD national surveillance study. Antimicrobial susceptibility testing… CONTINUE READING